Since December, 2019, coronavirus disease 2019 (COVID-19) has been an international public health emergency.[@bib1], [@bib2], [@bib3] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mimics the influenza virus regarding clinical presentation, transmission mechanism, and seasonal coincidence.[@bib3] Thus, co-infection by both viruses is feasible. To the best of our knowledge, only one case of co-infection is known, although the diagnosis was sequential.[@bib4] Here, we present four cases of SARS-CoV-2 and influenza co-infection, diagnosed simultaneously.

Patients 1--3 were men aged 53, 78, and 56 years, respectively, and patient 4 was a woman aged 81 years ([table](#tbl1){ref-type="table"} ). All four patients had a medical history of hypertension. Patients 1 and 4 had a history of end-stage kidney disease on haemodialysis, and patients 2 and 4 had type 2 diabetes. All four patients attended the emergency department because of non-productive cough, fever, and dyspnoea for 3 days.TableAnalytical findings of four patients with severe acute respiratory syndrome coronavirus 2 and influenza virus co-infection**CRP (mg/dL \[\<1 mg/dL\])LDH (U/L \[\<234 U/L\])Ferritin (ng/mL \[20--400\])D-dimer (ng/mL \[\<500\])Lymphocyte count (×10^9^ cells per L \[0·9--4·5\])Platelets count (×10^9^ cells per L \[130--400\])Ultrasensitive troponin I (ng/L \[\<45·2\])**0 h24 h72 h0 h24 h72 h0 h24 h72 h0 h24 h72 h0 h24 h72 h0 h24 h72 h0 h24 h72 hPatient 1 (man, 53 years)4·31010NA191209NA9051203NA70013000·60·40·312510186191168300Patient 2 (man, 78 years)14·015·03·6314340283NA162235NANA21000·30·30·5606081NANANAPatient 3 (man, 56 years)2·13·18NANANANA280305NA200200NA1·21·8NA199205NA2·82·9NAPatient 4 (woman, 81 years)1·36·19·7247231250NANANA200NANA0·50·50·79978781748648836[^1]

Physical examination revealed tachypnoea and bronchospasm with low oxygen saturation for all patients except for patient 3, whose values were normal. Chest radiography at admission was pathological in two patients: patient 2 had bilateral infiltrates, and patient 4 had a right bilobar pneumonia. The analytical findings are summarised in the [table](#tbl1){ref-type="table"}.

Rapid nucleic acid amplification test for influenza A was positive in patients 1 and 2. Patient 3 tested positive for both influenza A and B, and patient 4 tested positive for influenza B. Following the local diagnosis protocol for SARS-CoV-2, simultaneous RT-PCR was done and was positive for all four patients. Patient 3 was discharged after 48 h without treatment or complications. However, rapid respiratory deterioration, orotracheal intubation, and mechanical ventilation were required for patients 1, 2, and 4.

We initiated treatment with lopinavir--ritonavir 400/100 mg twice a day, oral hydroxychloroquine 200 mg twice a day (in haemodialysis patients, 100 mg twice a day), and oral oseltamivir 150 mg twice a day (in haemodialysis patients, 30 mg every 48 h). Subcutaneous interferon β-1b 8MU was added every 48 h in patients 2 and 4. Patient 1 showed clinical improvement and 72 h after admission he remained stable with minimal oxygen requirements. Patients 1 and 4 remained under mechanical ventilation 72 h after admission.

Here we highlight four cases of SARS-CoV-2 and influenza co-infection and show the implications that such a co-infection can have. The clinical and analytical courses in these patients did not differ from those previously reported for COVID-19.[@bib5] However, more studies are needed to assess the effect of the SARS-CoV-2 and influenza co-infection in clinical outcomes. We call on the medical community to be aware and take COVID-19 into account as a potential diagnosis even in patients with other viral causes, especially in epidemic areas.
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[^1]: Numbers in square brackets correspond to the normal laboratory values. CRP=C-reactive protein. LDH=Lactate dehydrogenase. NA=not available.
